Overview

Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Status:
Terminated
Trial end date:
2019-10-09
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the efficacy and safety of UX007 in the treatment of disabling paroxysmal movement disorders associated with Glut1 DS.
Phase:
Phase 3
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc